BBI生命科學有限公司 01035Stock Information

Stock Information · Old Rules
// Company Overview //
Stock NameBBI生命科學有限公司
Stock Code01035
Company Full NameBBI生命科學有限公司
Industry醫療保健
Principal Activities集團主要從事用于科學研究的多種生命科學產品的開發、制造及銷售,并提供生命科學相關服務。
Listing Date2014-12-30
Listing Rules EraOld Rules
Listing Rules ChapterNo data
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市松江區香閔路698號
Business Address (Hong Kong)No data
Place of IncorporationNo data
Listing MethodNo data
Listing BoardMain Board
Websitehttp://www.bbi-lifesciences.com
Share Registrar香港中央證券登記有限公司
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo data
// Offering Information //
Prospectus Date2014-12-16
Offer PriceHK$ 1.75 / shares
Total Funds RaisedHK$ 68,864,250
// Valuation & Financials //
Market Cap (at Offer Price)HK$ 0
// Price Chart //
Loading...
// Use of Proceeds
Use of Proceeds1、約30.50%或61.5百萬港元,將用于深化產品及服務組合。我們擬于二零一六年應用所得款項凈額于此用途; 2、約18.60%或37.5百萬港元,將用作拓寬產品及服務組合; 3、約36.20%或73.0百萬港元,將用作建設與深化及拓寬我們產品及服務組合的上述策略有關的新工廠; 4、約4.50%或9.1百萬港元,將用作加強信息技術能力; 5、約7.20%或14.5百萬港元,將用于通過設立新的分公司拓展我們的直銷網絡; 6、約3.00%或6.1百萬港元,將用作加強網上銷售平臺及培養網上客戶群。
// Underwriting Syndicate //
独家保荐人 (1)
海通国际资本有限公司
整体协调人 (1)
海通国际资本有限公司
联席账簿管理人 (1)
海通国际资本有限公司
联席牵头经办人 (1)
海通国际资本有限公司
// Cornerstone Investors //
#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Pine River China Master Fund Ltd. 36,078,000 HKD 3.90% 6 months 2015-06-30
2 中国新经济投资有限公司 18,039,000 HKD 2.00% 6 months 2015-06-30
3 中国新锐医药控股有限公司 18,039,000 HKD 2.00% 6 months 2015-06-30
// Directors & Management //
Chairman王啟松
Company Secretary伍秀薇,胡恒
No director data available.
// Major Shareholders //
Major Shareholders & Holdings王啟松(57.24%),Grandeur Peak Global Advisors, LLC(9.07%),Matthews International Capital Management, LLC(5.99%)
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics